Fifer, Simon
Godsell, Jenni
Opat, Stephen
Hamad, Nada
Lasica, Masa
Forsyth, Cecily
Morand, Louisa
Smeaton, Erica
Winton, Sharon
Puig, Andrea
McGeachie, Marija
Funding for this research was provided by:
Janssen Australia (N/A, N/A, N/A, N/A)
Article History
Received: 4 March 2024
Accepted: 2 July 2024
First Online: 11 July 2024
Declarations
:
: This study was approved by the Human Research Ethics Committee, Bellberry Limited on 23rd June 2022, Application number: 2022-05-448. All participants in the study provided written informed consent.
: Not applicable.
: S Fifer and J Godsell are employees of CaPPRe. CaPPRe has consulted to AbbVie, Amgen, AstraZeneca, Celgene, CSL Behring, Edwards, GSK, Ipsen, Janssen, Novo Nordisk, Roche, Sanofi, Shire and UCB, outside of the submitted work. S Opat has received research funding, honoraria and consulted to AbbVie, AstraZeneca, BeiGene, CSL Behring, Gilead, Ipsen, Janssen, Merck and Roche. N Hamad has received honoraria from AbbVie, AstraZeneca, BeiGene, CSL Gilead, Genentech, Janssen, Novartis and Roche. A Puig and M McGeachie are employees of Janssen-Cilag Australia Pty LtdĀ (a Johnson and Johnson company). The authors report no other competing interests.